Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Closes
- Oct 20, 2027 (in 416 days)
Similar opportunities open now
- Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Oct 2027Up to $750K
- Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Oct 2027Up to $750K
- Translational Neural Devices (R61/R33 - Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Jan 2027
- Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Jul 2027
- First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Oct 2027
Classification and identifiers
- Solicitation number
- PAR-25-225
- Assistance listing (CFDA)
- 93.853
Amount
Amount not published by the funder
Who can apply
State government agencies, Local government agencies, Nonprofits, including small and volunteer-run organizations, and Small businesses can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this opportunity
Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.